Biotech

0 591
Eagle Test Systems Common Stock EGLT Stock News

Egalet Corporation (NASDAQ: EGLT) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced news from the FDA that proved to be overwhelmingly positive, leading to excitement among investors. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to EGLT ahead.





EGLT Gains On FDA News

As mentioned above, Egalet Corporation is having an overwhelmingly strong start to the trading session after announcing news from the United States Food and Drug Administration. According to the press release, the FDA has granted tentative approval for an expanded label for ARYMO ER tablets. The treatment has been approved for the management of severe pain that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.




ARYMO ER was developed using the EGLT proprietary GuardianTM Technology. This is a physical and chemical barrier approach to abuse deterrence without the use of an opioid antagonist. In a statement, Mark Strobeck, Ph.D., CEO at EGLT, had the following to offer:

“Given that extended-release morphine is the most frequently prescribed ER opioid for individuals living with chronic pain and the majority of those prescriptions are in easy to abuse formulations, we believe that strengthening the ARYMO ER label to include additional abuse-deterrent data is an important improvement for chronic pain patients and their communities… While opioids should be reserved for situations when all other alternative therapies have been tried, when opioids are needed, having abuse-deterrent options is important.”

What We’re Seeing From The Stock

As investors one of the first things that we learn is that the news moves the market. Of course, the news surrounding Egalet Corporation proved to be overwhelmingly positive, causing excitement among investors and sending the stock toward the top. Currently (10:07), EGLT is trading at $1.20 per share after a gain of $0.19 per share or 18.79% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on EGLT. In particular, we’re interested in following the sales surrounding ARYMO ER. With the strong label change, sales should increase. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 543
Ampio Pharmaceuticals Inc AMPE Stock News

Ampio Pharmaceuticals Inc (NYSEAMERICAN: AMPE) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced positive results from a key Phase 3 clinical trial. Below, we’ll talk about the results, what we’re seeing from the stock as a result, and what we’ll be watching for with regard to AMPE ahead.





AMPE Announces Positive Clinical Results

As mentioned above, Ampio Pharmaceuticals is having an overwhelmingly strong start to the trading session today after announcing clinical results. The results came from the Phase 3 clinical trial of AmpionTM. The treatment is designed for those with severe osteoarthritis of the knee.




In the press release, AMPE said that the Phase 3 clinical trial met the primary endpoint, with 71% of treated patients meeting the OMERACT-OARSI responder criteria. According to the announcement, responders experienced an average of 53% decrease in pain as measured by WOMAC A and a 50% improvement in function. Also, patients experienced a 45% improvement in quality of life as measured by Patient Global Assessment (PGA).

AMPE also said that the treatment met its secondary endpoints. First and foremost, treated patients achieved statistical significance in composite endpoint of pain and function from baseline in both categories at 12 weeks. This data was supported by an increase in quality of life. Also, when treated with Ampion, patients experienced a significant improvement in a composite endpoint of pain and function compared to all KL 4 saline-treated patients. Finally, AMPE said that the treatment proved to be well tolerated. In a statement, Michael Macaluso, Chairman and CEO at AMPE, had the following to offer:

“We are very pleased with the positive Phase 3 data as we believe that Ampion will address an unmet medical need, providing severely diseased patients a non-opioid option that not only reduces pain, but also improves function and quality of life in a meaningful way.

We are hopeful that Ampion will serve as a safe and effective treatment for an incurable, progressive disease that afflicts 21 million people in the U.S. and over 200 million people worldwide who suffer from osteoarthritis. We look forward to working closely with the U.S. Food and Drug Administration (FDA) as we prepare to submit our Biologics License AGreement (BLA) for Ampion.”

How The Stock Is Reacting To The News

One of the first things that we learn as investors is that the news moves the market. That’s proving to be the case today. With the strong clinical results and coming BLA with the FDA, investors are excited, sending the stock toward the top. At the moment (10:12), AMPE is trading at $2.79 per share after a gain of $1.04 per share (59.43%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on AMPE. In particular, we’re interested in following the story surrounding Ampion and excited for the BLA, which will likely come next year. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 363
Teva Pharmaceutical Industries Ltd (ADR) TEVA Stock News

Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA) is having an incredibly strong start to the trading session this morning after the company announced a massive string of layoffs. Today, we’ll talk about the news, what we’re seeing from the stock as a result, and what we’ll be watching for with regard to TEVA ahead.





TEVA To Lay Off Thousands Of Workers

As mentioned above, Teva Pharmaceutical Industries is having a strong day in the market today after announcing thousands of layoffs. The world’s largest generic drug maker said that it would lay off 14,000 workers as part of the plans to restructure itself around the world and salvage the struggling company.

In a statement, TEVA said that the layoffs represent about 25% of the company’s entire global workforce. These cuts will take place over the next 2 years with most layoffs expected to take place in the year 2018. As a result, TEVA is expecting that costs will be cut by approximately $3 billion by the end of the year 2019. In a letter to employees, Kare Schultz, CEO at TEVA, had the following to offer:




“[Restructuring is] crucial to restoring our financial security and stabilizing our business. We have no time to waste… we are flattening our organization both top down and sideways, with fewer layers of management and increased accountability. This will ensure better integration, improve productivity and efficiencies, and reduce our cost base.”

What We’re Seeing From The Stock

As is always the case, the news moves the market. In this particular case, TEVA is making a gigantic step in the right direction when it comes to cost reduction and getting their business back on a strong financial foundation. As a result, investors are excited, pushing the value of the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:49), TEVA is trading at $17.70 per share after a gain of $2.00 per share or 12.74% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TEVA. In particular, we’re interested in following the layoffs and the restructuring process. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 444
pSivida PSDV Stock News

pSivida Corp. (NASDAQ: PSDV) is having a pretty strong start in the pre-market this morning after the company announced results from a Phase 1 clinical trial. Of course, the results were positive, leading to excitement among investors. Below, we’ll talk about the results, how the news is affecting the stock, and what we’ll be watching for ahead.





PSDV Gains On Trial Results

As mentioned above, pSivida is having a strong start to the trading session this morning after the company released results from a Phase 1 clinical trial. The trial was a safety and exploratory efficacy pilot study surrounding a sustained release implant integrating the company’s DurasertTM delivery technology and an HSS-designed implantable device.

The implant being tested in the study was designed to deliver a continuous low dose of dexamethasone into the knee joint over the course of several months. In the press release, PSDV said that six subjects, screened for radiologically-confirmed and symptomatic osteoarthritis of the knee, were enrolled for a study duration of six months. Throughout treatment, average weekly pain scores were compared against baseline. Safety monitoring included serial radiographs and plasma dexamethasone concentrations.




The results showed that patients experienced an average of 3.8 point reduction in average weekly pain on a 10-point scale. Also, PSDV said that the results did not diminish over the 24-week period. Also, Plasma dexamethasone concentrations were found to be lower than those reported by other standard-of-care treatments and no adverse events were reported. In a statement, Dr. Robert N. Hotchkiss, co-inventor of the implant and Medical Director of Innovations at HSS, had the following to offer:

“This is a very promising start of a collaboration, combining the know-how, experience and technology of the pSivida team with the clinical expertise and insight of HSS. With the ageing and more active population, we are in need of novel and perhaps superior treatment alternatives for pain relief in arthritis.”

The above statement was followed up by Nancy Lurker, President and CEO at PSDV. Here’s what she had to offer:

“The positive Phase 1 data demonstrates that Durasert technology has applications beyond our core back-of-the-eye disease markets… We believe patients suffering from severe knee OA deserve better non-narcotic, non-opioid options to help manage their pain, and our collaboration with HSS to apply our technology to these patients has the potential to provide longer-term relief of their pain.”

What We’re Seeing From The Stock

As we all know, the news moves the market. With positive clinical data breaking at the moment, it’s no surprise that we’re seeing strong movement out of pSivida. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (8:38), PSDV is trading at  $1.19 per share after a gain of $0.04 per share (3.48%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on PSDV. In particular, we’re interested in following the progress after the positive trial results. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Aytu Bioscience Inc AYTU Stock News

For the superstitious, things tend to happen in three’s. And, while an investment thesis should not necessarily get predicated on such an event, for those watching the growth of Aytu BioScience (NasdaqCM: AYTU), the phenomenon may again be proving itself to be more than just an anomaly.

Investors are already pleased with the record-breaking growth of Natesto®, the company’s marketed FDA-approved product indicated for testosterone replacement. They are also cheering on MiOXSYS®, AYTU’s rapid semen analysis system that is gaining popularity as the emerging standard of care diagnostic system to assess male infertility caused by oxidative stress. But alas, for those that seek solace in knowing that GOOD things tend to “happen in three’s,” AYTU will not disappoint.

Meet Fiera®, AYTU’s novel sexual wellness device targeting the female side of the multi-billion dollar sexual dysfunction (SD) market. And, for AYTU, this unique product adds a third lynchpin to the company’s growing arsenal of revolutionary pipeline products.

Fiera®’s Proven Effectiveness

Already available on the market, Fiera® is clinically proven to promote sexual desire and arousal for women by providing both gentle suction and light stimulation. Leaving behind the need for costly drugs with the potential for severe and known side effects, Fiera® offers an external, hands-free solution that provides an alternative and practical answer to help overcome issues related to decreased female sexual desire.

Initially developed by Nuelle, and subsequently acquired by AYTU in an all-stock transaction, Fiera® is the culmination of a collaborative effort made by engineers and sexual wellness professionals. The joint effort focused on developing an over-the-counter, drug-free solution for women, thus facilitating a means to generate results for women similar to how Viagra® works for men by increasing blood flow to the genitals. And, they were successful.

Both discreet and effective, Fiera® works by providing gentle suction and mild stimulation delivered in a manner that enhances a women’s blood flow to the genitals, increases natural lubrication and is shown to improve the overall readiness for sexual intimacy. The reception to Fiera® is overwhelmingly positive.

In a scientifically-based study of women aged 25-75 that are both pre and post-menopausal, 97% of the participants reported feeling more sexually aroused and 93% said that Fiera® helped them to generate more interest for sexual intimacy. Importantly, a sizable portion of the study group, roughly 87%, reported feeling as prepared and ready for sex as their partner, with a resounding 96% of them also stating that the device has once again made them look forward to and excited about sexual intimacy and intercourse. Of prime importance, though, the study results further demonstrate that the benefits from Fiera® are achieved in an average of only five minutes, highlighted again by the fact that Fiera® offers a drug-free alternative to currently available treatments. Furthermore, the device can be discreetly purchased either online or through a doctor’s office without a prescription.

The Multi-Billion Dollar Female Sexual Dysfunction Market

Proving itself as both effective and easy to use, AYTU is positioning Fiera® to reap the rewards from an estimated $10 billion developing sexual wellness industry. With clinical data validating that Fiera® is effective, and perhaps better than many prescription based alternatives, AYTU is implementing an aggressive strategy to penetrate new and existing markets designed to increase market share and capitalize on the industry’s hunger to acquire products to address women’s sexual wellness. Hologic, for instance, recently purchased Cynosure (NasdaqGS: CYNO) in a deal that is expected to bring over $1.65 billion in value to Cynosure shareholders. For their part, Valeant (NYSE: VRX) paid approximately $1 billion for Sprout’s Addyi®, often referred to as the “female Viagra®” in a deal that sought to develop the drug into a multi-billion dollar franchise. And, while the troubled VRX recently announced that they are giving Addyi® back to its original owner, citing women’s reluctance to take a drug-induced solution, the terms of the original deal support the intensity of interest for stamping a competitive footprint inside of this developing market. Not only that, the fact that women are hesitant to use drugs to address their sexual issues further supports the place and role of Fiera®.

Keenly aware of how the female sexual wellness market is developing, AYTU is gearing up sales and marketing efforts to exploit the weaknesses of currently available products and to follow a marketing strategy that is generating product adoption and placement success for Natesto® and MiOXSYS®, respectively.

Capitalizing On Fiera®’s Benefits

Positioned as the third revenue-generating component of AYTU’s developing commercial product pipeline, Fiera® is taking it’s clinically proven, expertly crafted personal care device to market in a big way. Capitalizing on the sleek, drug-free, and unobtrusive design of Fiera®, AYTU is on task to educate the market of the benefits from its clinically proven drug-free method for delivering a fast-acting sexual desire solution to women. Now that the market is aware of users’ resistance to taking drugs like Addyi®, AYTU is stepping up its campaign to take advantage of a market population that is wary of options that provide mediocre results that often bring with it severe physical and emotional side effects.

For Fiera®, perhaps the only thing that has held back it’s market success is the lack of aggressive inclusion in the AYTU development plan. But, now flush with cash that is expected to bring the company toward break-even or EPS levels within the next eighteen months, AYTU is gearing up to maximize the value of this potentially lucrative asset. Management is not only expected to promote the benefit of Fiera® as being safe, useful and appealing to women, but investors can expect that AYTU will fund a strategy to educate users about the safety, speed, and drug-free attributes of Fiera® to exploit the substantial and growing market opportunity.

For investors, knowing that AYTU has less than five million shares outstanding, and a cash balance of roughly $7 million, the impact that a successful Fiera® campaign can bring is substantial. Factoring in the history that both Hologic and Valeant paid more than a billion dollars to play in this market provides a confident nod of approval as well. And, if Fiera® continues to validate its position as a viable and effective alternative solution for women plagued by sexual issues, Fiera® may prove its value to shareholders many times over. Hence, if AYTU stays the course in marketing its pipeline correctly, they may ultimately generate substantial returns in three distinct market segments, bringing shareholders a trifecta ticket of diversified success.

0 486
Verastem Inc VSTM Stock News

Verastem Inc (NASDAQ: VSTM) is having an overwhelmingly strong start to the trading session in the pre-market hours this morning, and for good reason. The company announced positive trial data from its Phase 3 DUO clinical trial over the weekend. Of course, this led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about what we saw in the press release, how the stock reacted to the news, and what we’ll be watching with regard to VSTM ahead.





VSTM Gains On Phase 3 Update

As mentioned above, Verastem is having an overwhelmingly strong start to the trading session this morning after announcing the presentation of results from a Phase 3 DUO study. The study was designed to evaluate the efficacy and safety of duvelisib as a treatment for relapsed or refractory chronic lymphocytic leukemia.

In the press release, VSTM announced that it would be presenting the data at the American Society of Hematology 2017 Annual Meeting. The meeting will be held from December 9th through December 12th in Atlanta. In a statement, Ian Flinn, MD, PhD, Director of the Blood Research Program at Sarah Cannon Research Institute and Lead Investigator of the VSTM clinical trail, had the following to offer:




“In the Phase 3 DUO study, oral duvelisib monotherapy achieved a statistically significant improvement in Progression-Free Survival versus the approved standard of care treatment ofatumumab, along with a well characterized and manageable safety profile, in patients with previously treated CLL/SLL… Similar PFS advantages were also observed across all analyzed patient subgroups, including patients with `7p deletion, a genotype that historically correlates with poorer clinical outcomes. Duvelisib also achieved a statistically significant improvement in Overall Response Rate and significantly reduced lymph node burden in the vast majority of patients. These data are encouraging for patients with CLL/SLL who progress or relapse following initial treatment.”

The above statement was followed up by Diep Le, MD, PhD, CMO at VSTM. Here’s what he had to offer:

“CLL/SLL mostly affects elderly patients and many are unable or unwilling to be hospitalized or come into the clinic for frequent IV infusions. The CLL/SLL treatment landscape therefore is moving away from chemotherapies and toward more targeted, preferably oral regimens… While patients are living longer many will be intolerant to, or relapse following, their initial therapy emphasizing the need for new options. Oral duvelisib is the first Pl3K inhibitor to show efficacy as an oral monotherapy in a randomized Phase 3 study in patients with relapsed or refractory CLL/SLL and may offer an appealing alternative for patients who have progressed or relapsed. We remain on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the first quarter of 2018 requesting full approval of duvelisib for the treatment of patients with relapsed or refractory CLL/SLL and accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma (FL).”

How The Stock Is Reacting To The News

As investors, one of the first things that we learn is that the news moves the market. Considering the overwhelmingly positive news released by Verastem, it’s no surprise that we’re seeing strong movement in the market. At the moment (8:03), VSTM is trading at $5.00 per share after a gain of $1.67 per share (15.47%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on VSTM. In particular, we’re interested in the next steps surrounding bringing duvelisib to market. Nonetheless, we’ll continue to follow the story close and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1116
Valeant Pharmaceuticals Intl Inc VRX Stock News

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is having an overwhelmingly strong start to the trading session this morning as investors start to pay more attention to the stock. The beleaguered pharmaceutical company has struggled since the Philidor scandal quite a while ago. However, with changes made by the company’s CEO Joseph Papa, the company seems to be getting on track. Today, we’ll talk about the big changes Papa has made, what we’re seeing from the stock, and what we’ll be watching with regard to VRX ahead.





VRX Is Benefiting From Joseph Papa As CEO

As mentioned above, Valeant Pharmaceuticals is having an incredibly strong day in the market today as investors start to pay attention to what the company is doing. Much of this can be attributed to Joseph Papa, the company’s CEO that took the company over when it was in shambles from the Philidor scandal. With massive concerns surrounding actual sales, alongside huge debts, the company was struggling in a big way.

However, since the company’s CEO, Joseph Papa took control, things started to improve in a big way. This can be seen largely by simply looking at the debt the company has. In April of 2016, Joseph Papa took over as the CEO of the company. Of course, at this time, the company was reeling from debt. In fact, when he took it over, VRX owed around $32 billion.




Since then, we’ve watched as Joseph Papa turned things around. In fact, when he took control of the company, his goal was to pay down $5 billion in debt from assets and divestitures and free cash flows by February of 2018. However, the company is far ahead of this goal. In fact, since Papa took over, the company has repaid approximately $6 billion in total debt since the first quarter of 2016. So, how has Papa done this?

His work has largely surrounded selling off non-core assets and using free cash flow to pay down debt. Well, these sales have gone faster than expected and the company’s free cash flows have come in at a rate faster than expected. Now, considering his outstanding performance, the big question is what will Joseph Papa come up with for aggressive goals in the coming months. We know that VRX is doing overwhelmingly well since he took over, and we know that debt is still a big priority. Where he is going with it next however, is something that we do not know. Nonetheless, considering his performance thus far, his coming plan is likely to be both aggressive and impressive.

What We’re Seeing From VRX Today

As mentioned above, investors are starting to realize the value proposition offered by Valeant Pharmaceuticals now that they are seeing the results of efforts made by Joseph Papa. As a result, we’re seeing strong gains in the market. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:42), VRX is trading at $18.96 per share after a gain of $1.33 per share or 7.54% thus far today!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on VRX. In particular, we’re interested in watching to see what the next aggressive plan is that Papa has for the company. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 501
TrovaGene Inc TROV Stock News

TrovaGene Inc (NASDAQ: TROV) is having an overwhelmingly strong start to the trading session this morning after the company released positive data surrounding a key clinical candidate in the field of breast cancer treatment. Today, we’ll talk about the data that was released, what we’re seeing from TROV, and what we’ll be watching for ahead.





TROV Gains On Data

As mentioned above, TrovaGene is having an incredibly strong start to the trading session after announcing key data. The preclinical data announced demonstrated the sensitivity of triple negative breast cancer, also known as TNBC, cell lines to PCM-075. PCM-075 is a highly selective Polo-like kinase 1 (PLK1) inhibitor. The company announced that the full preclinical data will be featured as a poster presentation at the 40th San Antonio Breast Cancer Symposium on December 7th. In a statement, Mark Erlander, Chief Scientific Officer at TROV, had the following to offer:




TNBC is a heterogeneous cancer with a poor prognosis. The marked synergy shown in preclinical studies with PCM-075 in combination with therapies, such as abiraterone acetate (Zytiga®), may provide a new therapeutic option for TNBC patients…”

How The Stock Reacted To The News

As investors, one of the first things that we learn is that the news moves the market. So, it’s no surprise that with overwhelmingly strong news out of TrovaGene, we’re seeing strong movement in the value of the stock. Of course our partners at Trade Ideas were the first to alert us to the gains. Currently, (10:00), TROV is trading at $0.57 per share after a gain of $0.04 per share or 8.47% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TROV. In particular, we’re interested in following the story surrounding PCM-075 as well as the rest of the company’s robust pipeline. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 464
Alexion Pharmaceuticals ALXN Stock News

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) is having an incredibly strong start to the trading session this morning and for good reason. News has hit the tape that an activist investor is putting pressure on the company to make changes. Today, we’ll talk about the breaking news, what we’re seeing from ALXN as a result, and what we’ll be watching for ahead.





Elliott Management Puts Pressure On ALXN

As mentioned above, Alexion Pharmaceuticals is having a strong start to the trading session this morning as reports surface that an activist investor is pressuring the company to make changes. According to various reports, Elliot Management is pushing the company to make major changes to the company’s board if ALXN doesn’t provide an outlined plan to boost growth.




The report first surfaced on the New York Times late on Thursday. Ultimately, Elliot management wants the company to release detailed plans to boost share prices by the end of the month. The firm is pushing ALXN to provide a strategy that includes a plan to potentially sell the company outright. If this doesn’t happen, reports suggest that the firm will begin a proxy fight for seats on the board of directors.

This news comes amid multiple recent downgrades. One of the most notable came from The Street’s Bruce Kamich who argued that the dynamics suggest that the stock is likely to remain on the defensive. Here’s what Kamich had to say about Alexion Pharmaceuticals:

In this daily bar chart of ALXN, below, we can see that ALXN is below both the declining 50-day line and the bearish 200-day moving average line… The daily On-Balance-Volume line topped in October and has turned lower telling us that selling pressure has become more aggressive.

The trend-following Moving Average Convergence Divergence (MACD) oscillator turned below the zero line at the end of October for an outright sell signal… The price action the past two or three weeks looks like a bearish continuation pattern so further declines would be anticipated.”

What We’re Seeing From The Stock

It is clear that investors are happy about Elliot stepping in and forcing the company to make changes. This can be seen by looking at the growth that we’re seeing in the stock this morning. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:44), ALXN is trading at $113.94 per share after a gain of $7.15 per share or 6.70% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on ALXN. In particular, we’re interested in following the story surrounding Elliot Management and their pressure on the company. We want to see how the company responds and whether or not it is willing to put itself up for sale. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 350
Entellus Medical Inc ENTL Stock News

Entellus Medical Inc (NASDAQ: ENTL) is having an incredibly strong start to the trading session this morning after acquisition news hit the tape. Of course, the news of the acquisition caused excitement among investors who sent the stock screaming for the top. Today, we’ll talk about the acquisition, what we’re seeing from ENTL as a result, and what we’ll be watching for ahead.





ENTL To Be Acquired By SYK

As mentioned above, Entellus Medical is having an overwhelmingly strong start to the trading session this morning after the company announced that it would soon be acquired. In a definitive merger agreement that was announced today, Stryker Corporation (NYSE: SYK) agreed to buy the company at a price of approximately $662 million. In a statement, Robert White, CEO at ENTL, had the following to offer:

The combination of Stryker’s established commitment to making healthcare better and Entellus’ innovative products within the ENT segment will continue to provide our customers the tools they need for cost effective solutions… I look forward to the additionally progress we will make together.”




How The Stock Reacted to The News

As investors, one of the first things that we learn is that the news moves the market. This proved to be a prime example of that as the stock soared! Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:33), ENTL is trading at $23.82 per share after a gain of $7.81 per share or 48.75% thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on the SYK acquisition of ENTL. Of course, as with any acquisition, this one is still subject to customary closing conditions. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 7498
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...